Skip to main content
Premium Trial:

Request an Annual Quote

Celera Diagnostics Strikes Deals With Quest, LabCorp

NEW YORK, Oct. 2 - Celera Diagnostics today said it has signed a pair of collaborations with Quest Diagnostics and Laboratory Corporation of America to determine the "clinical utility" of lab tests for a variety of diseases.

 

Terms of the deal call for Quest to receive exclusive yet temporary access to markers with potential clinical usefulness in cardiovascular disease and diabetes. LabCorp gets that deal but only for Alzheimer's disease and breast and prostate cancer.

 

In exchange, Celera Diagnostics, which will run the disease association studies for the collaboration in-house, said it will become "a preferred vendor" to both clinical diagnostics powerhouses.

 

Click here for more information on the LabCorp deal, and here for the Quest deal.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.